Kwang-Soo Kim, PhDDirector, Molecular Neurobiology Laboratory
About Dr. Kim
Kwang-Soo Kim, PhD, has over 25 years of experience investigating molecular and developmental neurobiology of the midbrain dopamine neuronal system in health and disease, focusing on elucidating the transcriptional mechanisms underlying development and maintenance of dopamine neurons. Dr. Kim’s Molecular Neurobiology Laboratory, founded in 1998, studies the biology of brain cells that rely on the brain chemical dopamine to communicate. Major brain disorders such as PD, ADHD, and schizophrenia are related to abnormalities affecting these cells. Parkinson’s, Alzheimer’s, and autoimmune diseases involve damage to specific cell types.
Based on basic transcriptional studies of midbrain dopamine neurons, Dr. Kim’s lab identified the orphan nuclear receptor Nurr1 as a potential drug target of Parkinson’s disease (PD) to develop novel drug candidates for neuroprotective and mechanism-based therapeutics. Promising compounds are being generated using established high throughput screening by medicinal chemistry and are being tested in preclinical animal models.
Dr. Kim’s lab also investigates translational stem cell research and personalized cell therapy of PD and is optimizing reprogramming and differentiation methods. His lab has pioneered the generation of clinical grade induced pluripotent stem (iPS) cells using non-viral reprogramming methods such as direct delivery of reprogrammed proteins and novel episomal methods, and has recently identified novel mechanisms underlying metabolic reprogramming during human induced pluripotency.
The search for effective treatments for Parkinson’s disease is ongoing. Join our mailing list to stay up to date on the latest advances.
Personalizing Stem Cell Therapy for Parkinson’s Disease
In the U.S. alone, as many as one million people have Parkinson’s disease. Kwang-Soo Kim, PhD, is committed to finding a way to lower those numbers.
First-in-Human Therapy With Stem Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease
MGH-McLean team have become the first to implant patient-derived midbrain dopaminergic progenitor cells into a patient with Parkinson’s.
Patient-Derived Dopamine Neurons Show Promise in Parkinson’s Treatment
A study published in the New England Journal of Medicine describes the innovative treatment of a Parkinson’s disease patient.